Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care
This study investigated a case of Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a tumor profiling test approved by the U.S. Food and Drug Administration (FDA) in 2017, to examine what factors would contribute to healthcare innovation. First, we set...
Main Authors: | Takaharu Jibiki, Hayato Nishimura, Shintaro Sengoku, Kota Kodama |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/14/3448 |
Similar Items
-
La sécurité des futures architectures convergentes pour des services personnalisés : aspect architectural et protocolaire
by: Hammami, Ali
Published: (2013) -
Problems of unknown significance: Counseling in the era of next generation sequencing
by: Fahrioğlu U
Published: (2018-10-01) -
Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
by: Simona Bruzas, et al.
Published: (2021-09-01) -
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
by: Matteo Allegretti, et al.
Published: (2018-03-01) -
Bioinformatics Workflow for Clinical Whole Genome Sequencing at Partners HealthCare Personalized Medicine
by: Ellen A. Tsai, et al.
Published: (2016-02-01)